quinoxalines has been researched along with Heart Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aalikhani, M; Alikhani, M; Bazi, Z; Oladnabi, M; Shamsabadi, F | 1 |
| Ameri, P; Angelini, A; Bornbaum, J; Cappello, P; Cimino, J; De Santis, MC; Di Bona, A; Franco, I; Ghigo, A; Heger, J; Hirsch, E; Lazzarini, E; Li, M; Lima, BHF; Lima-Júnior, RCP; Margaria, JP; Martini, M; Mongillo, M; Morello, F; Novelli, F; Perino, A; Pianca, N; Pirozzi, F; Porporato, PE; Rohrbach, S; Rossi, L; Sala, V; Sandri, M; Schulz, R; Sciarretta, S; Teixeira, MM; Tocchetti, CG; Zaglia, T | 1 |
| Aubin, HJ; Benhaddi, H; Bolin, K; de Nigris, E; Marbaix, S; Mork, AC; Wilson, K | 1 |
| Grief, SN | 1 |
1 review(s) available for quinoxalines and Heart Diseases
| Article | Year |
|---|---|
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Humans; Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline | 2011 |
3 other study(ies) available for quinoxalines and Heart Diseases
| Article | Year |
|---|---|
In silico drug repurposing for the treatment of heart diseases using gene expression data and molecular docking techniques.
Topics: Aminoisobutyric Acids; Aminopterin; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Daunorubicin; Digoxin; Drug Repositioning; Gene Expression; Heart Diseases; Humans; Lactams, Macrocyclic; Leucine; Ligands; Methylergonovine; Molecular Docking Simulation; Morpholines; Proline; Quinoxalines; Sulfonamides | 2021 |
Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; Autophagy-Related Proteins; Breast Neoplasms; Cardiotoxicity; Class Ib Phosphatidylinositol 3-Kinase; Cytoprotection; Disease Models, Animal; Doxorubicin; Female; Genes, erbB-2; Heart Diseases; Mice, Inbred BALB C; Mice, Transgenic; Mutation; Myocytes, Cardiac; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Thiazolidinediones; Toll-Like Receptor 9; Tumor Burden | 2018 |
Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
Topics: Adolescent; Adult; Aged; Benzazepines; Cost-Benefit Analysis; Europe; Female; Heart Diseases; Humans; Incidence; Lung Neoplasms; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinoxalines; Smoking; Smoking Cessation; Stroke; Varenicline; Young Adult | 2009 |